Systemic strategies for osteosarcoma: advances and future directions.

Area of Science:

• Pediatric Oncology
• Skeletal Biology
• Cancer Therapeutics

Background:

• Osteosarcoma is an aggressive bone cancer predominantly affecting children and adolescents.
• Current treatments (surgery, chemotherapy, radiotherapy) have limitations, including severe side effects and a challenging prognosis, especially in advanced stages.
• Limb-sparing surgery has improved, but survival rates for localized and advanced osteosarcoma remain a concern (5-year survival: 60-70% for localized).

Purpose of the Study:

• To review the current landscape of osteosarcoma treatment.
• To highlight emerging therapeutic strategies beyond conventional approaches.
• To discuss the potential of novel therapies to improve patient outcomes and reduce treatment toxicity.

Main Methods:

• Review of existing literature on osteosarcoma treatment modalities.
• Analysis of current research trends in targeted therapies and immunotherapy for osteosarcoma.
• Exploration of novel therapeutic avenues including gene therapy and advanced drug delivery systems.

Main Results:

• Chemotherapy remains a cornerstone but is associated with significant adverse effects.
• Targeted therapies (e.g., IGF-1R inhibitors, tyrosine kinase inhibitors) and immunotherapies (e.g., checkpoint inhibitors, CAR-T cell therapy) show promise for more precise cancer cell targeting.
• Gene therapy and innovative drug delivery systems are under investigation as potential future treatments.

Conclusions:

• Despite advances, osteosarcoma treatment remains challenging, necessitating the development of more effective and less toxic therapies.
• Targeted therapies and immunotherapies represent promising frontiers in osteosarcoma treatment, aiming for improved efficacy and reduced side effects.
• Continued research and development in novel therapeutic approaches are crucial for significantly improving the prognosis for patients with osteosarcoma.